VENTYX BIOSCIENCES, INC. VTYX 深 滬
等待開盤 10-27 09:30:00 美东时间
5.81
-0.790
-11.97%
華盛通- 最 高6.96
- 今 開6.76
- 成交量 1247.50万股
- 最 低 5.74
- 昨 收 6.60
- 總市值 4.14亿
- 52周最高 7.82
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 0.783
- 委 比 59.92%
- 總股本 7130.85万
- 歷史最高 47.2508
- 量 比 0.44
- 振 幅 18.48%
- 歷史最低 0.783
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | VTYX大涨71%！新药研究取得积极结果；SEV转型为公益公司，涨近58%
VTYX大涨71%！新药在肥胖和心血管风险因素患者中的2期研究取得积极结果；SEV转型为公益公司，涨近58%>>
10-24 15:16
Ventyx Stock Is Rallying Thursday: What's Driving The Surge?
Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232.
10-24 01:40
What's Driving Beyond Meat's 11% After-Hours Drop?
Beyond Meat shares fell 11% after hours following a volatile rally sparked by ETF inclusion and short-selling activity.
10-23 13:50
Why Ventyx (VTYX) Shares Soared 86.5% After Hours?
Ventyx shares jumped 86.5% in after-hours trading after positive Phase 2 trial results.
10-23 12:34
Ventyx Biosciences shares are trading higher after the company announced results from its Phase 2 study of VTX3232 in participants with obesity and cardiovascular risk factors.
Ventyx Biosciences shares are trading higher after the company announced result...
10-23 04:47
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors
VTX3232 demonstrated significant reductions in cardiovascular risk factors, including an ~80% reduction in hsCRP and IL-6 levels below the threshold for CV risk. Combining VTX3232 with semaglutide showed additional benefits in reducing inflammation and liver inflammation. VTX3232 was safe and well-tolerated, with adverse events comparable to placebo. The Phase 2 study highlights VTX3232’s potential as a novel oral anti-inflammatory therapy for ca...
10-22 20:02
美股大行评级 | 潜在涨幅162.68%！Ocular Therapeutix获JMP证券升目标价至29美元，维持"跑赢大市"评级
今日重点评级关注：JMP证券：维持Ocular Therapeutix"跑赢大市"评级，目标价从20美元升至29美元；汇丰银行：上调Banco BBVA Argentina评级至"买入"，目标价从21美元下调至17美元
10-02 15:08
Clear Street Initiates Coverage On Ventyx Biosciences with Buy Rating, Announces Price Target of $11
Clear Street analyst Kaveri Pohlman initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces Price Target of $11.
10-01 20:57
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
Ventyx Biosciences executives will participate in three upcoming investor conferences: the 2025 Wells Fargo Healthcare Conference in Boston on September 5, and both the Morgan Stanley 23rd Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8. A webcast of the Wells Fargo presentation will be available on the company's website, www.ventyxbio.com, with a replay accessible fo...
08-27 11:02
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers FibroGen (NASDAQ:FGEN) shares rose 20.1% to $10.11 during Monday's aft...
08-12 05:06
